Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody that targets a pyroglutamate amyloid beta (Abeta) epitope at the N-terminus, showing potential for early Alzheimers disease research [1] [2].
Purity:
95.00%
CAS Number:
[1931944-80-7]
Target:
Beta Amyloid|||Microtubule Associated
* VAT and and shipping costs not included. Errors and price changes excepted